Cellectar Biosciences, Inc.
CLRB
$3.69
$0.071.93%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 69.70% | -492.55% | 75.21% | 70.11% | 16.30% |
| Total Depreciation and Amortization | -23.76% | -15.76% | -36.38% | -2.00% | 66.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -90.86% | 100.71% | -94.03% | -154.26% | -63.03% |
| Change in Net Operating Assets | -107.93% | 111.80% | -67.82% | -104.02% | 200.24% |
| Cash from Operations | 53.36% | 63.83% | 29.77% | -13.73% | -13.62% |
| Capital Expenditure | -- | -- | -- | 77.02% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 77.02% | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -67.04% | -- | -- | -100.00% | 4,937.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -67.04% | -- | -- | -100.00% | -21.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -81.97% | 79.78% | -130.80% | -16.49% | -39.32% |